Full Text View
Tabular View
No Study Results Posted
Related Studies
Pulmonary Hypertension in Trisomy 21 Patients
This study is ongoing, but not recruiting participants.
First Received: May 22, 2007   Last Updated: May 23, 2007   History of Changes
Sponsored by: Children's Healthcare of Atlanta
Information provided by: Children's Healthcare of Atlanta
ClinicalTrials.gov Identifier: NCT00478296
  Purpose

Evidence has shown poor outcome for adult patients with pre-operative pulmonary hypertension following closure of an atrial septal defect.

Life-threatening pulmonary hypertensive crises may occur in these patients when they no longer have an atrial communication to decompress high right heart pressures. This concern has led some to advocate fenestrated patch closure of ASDs in patients with pulmonary hypertension with the prospect of a repeated procedure in order to close the fenestrations at a later date.


Condition
Congenital Disorders

Genetics Home Reference related topics: Down syndrome
MedlinePlus related topics: Down Syndrome High Blood Pressure Pulmonary Hypertension
Drug Information available for: Sildenafil Bosentan
U.S. FDA Resources
Study Type: Observational
Study Design: Natural History, Longitudinal, Defined Population, Retrospective Study
Official Title: Case Report: Resolution of Pulmonary Hypertension With Sildenafil and Bosentan in Patients With Trisomy 21 and Atrial Septal Defect

Further study details as provided by Children's Healthcare of Atlanta:

Estimated Enrollment: 1
Detailed Description:

Pre-operative resolution of pulmonary hypertension would clearly provide the best long-term outcome for these patients, allowing a definitive surgical procedure. There are no reported cases of resolution of pulmonary hypertension with the use of pulmonary vasodilators allowing successful ASD closure.

We report the case of a patient with trisomy 21 and a primum atrial septum defect with associated cleft mitral valve who was diagnosed with pulmonary hypertension at 8 days of life. Elevated pulmonary pressures were documented by cardiac catheterization during which the patient was found to have minimally responsive pulmonary vasculature to the administration of oxygen. He was started on pulmonary vasodilators which were continued for the following 5 months which resulted in gradual reduction in estimated PA pressure allowing successful closure of the primum ASD and repair of the cleft mitral valve. Following surgery, he was not restarted on pulmonary vasodilators and has continued to do well. The ability to reverse his pulmonary hypertension through the use of pulmonary vasodilators made him a candidate for his successful, definitive surgical repair. He currently has no residual cardiac problems and requires no cardiac medications. There will be no patient follow-up.

  Eligibility

Ages Eligible for Study:   up to 8 Days
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • case report of a patient with trisomy 21 and primum atrial septum defect with associated cleft mitral valve who was diagnosed with pulmonary hypertension at 8 days of life

Exclusion Criteria:

  • those who do not fit into inclusion criteria
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00478296

Locations
United States, Georgia
Children's Healthcare of Atlanta
Atlanta, Georgia, United States, 30322
Sponsors and Collaborators
Children's Healthcare of Atlanta
Investigators
Principal Investigator: heather m phelps, DO Children's Healthcare of Atlanta
  More Information

No publications provided

Study ID Numbers: 07-021
Study First Received: May 22, 2007
Last Updated: May 23, 2007
ClinicalTrials.gov Identifier: NCT00478296     History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by Children's Healthcare of Atlanta:
Pulmonary hypertension
Sildenafil
Bosentan
Trisomy 21
Atrial septal defect

Study placed in the following topic categories:
Heart Septal Defects
Aneuploidy
Heart Diseases
Cardiovascular Abnormalities
Vascular Diseases
Chromosome Disorders
Sildenafil
Trisomy
Bosentan
Heart Septal Defects, Atrial
Mental Retardation
Respiratory Tract Diseases
Genetic Diseases, Inborn
Hypertension, Pulmonary
Lung Diseases
Chromosome Aberrations
Abnormalities, Multiple
Neurologic Manifestations
Congenital Heart Septum Defect
Down Syndrome
Congenital Abnormalities
Heart Defects, Congenital
Neurobehavioral Manifestations
Hypertension

Additional relevant MeSH terms:
Heart Septal Defects
Aneuploidy
Heart Diseases
Cardiovascular Abnormalities
Nervous System Diseases
Vascular Diseases
Chromosome Disorders
Trisomy
Heart Septal Defects, Atrial
Mental Retardation
Pathologic Processes
Respiratory Tract Diseases
Genetic Diseases, Inborn
Hypertension, Pulmonary
Lung Diseases
Chromosome Aberrations
Abnormalities, Multiple
Neurologic Manifestations
Cardiovascular Diseases
Down Syndrome
Congenital Abnormalities
Heart Defects, Congenital
Neurobehavioral Manifestations
Hypertension

ClinicalTrials.gov processed this record on May 07, 2009